The BARC Score report for Integrated Planning and Analytics focuses on the market for integrated planning and analytics products and portfolios in the DACH region (Germany, Austria and Switzerland). It analyzes the strengths and challenges of all the leading vendors as well as several smaller vendors that often have less visibility, but still offer outstanding value to their customers.
Every vendor is evaluated on two dimensions: “Portfolio Capabilities” and “Market Execution”. Each represents one axis on the Score chart. These two dimensions include the following sub-criteria.
In general, portfolio capabilities reflect functional criteria (e.g., planning, formatted reporting, ad hoc query, analysis, dashboarding and predictive analytics) and criteria related to architecture. A special emphasis is placed on the integration of planning and analytics functionality within the vendors’ product portfolios. Ease of use for business users is also an important evaluation criterion.
Market execution takes into account the vendors’ product, sales and marketing strategies as well as certain organizational, financial and geographical considerations.
There are two main inclusion criteria for this BARC Score: the first is associated with each vendor’s products and the other is linked to the financial results relating to those products.
Functionality for planning (including write-back of planning data to a central database and other advanced planning features such as workflows, simulation, etc.) is the entrance ticket to be evaluated in this BARC Score.
Moreover, a vendor has to supply additional functionality for all four technologies from the following platform portfolio in a solution not merely focused on one industry or use case:
In addition, the vendor has to generate a minimum of 3 million EUR in license revenue per year with the above product set in German-speaking countries (Germany, Austria and Switzerland).
Vendors with an open source business model are evaluated by their total revenue because they charge an annual subscription fee rather than a license fee for their products.